AccueilDCTH • NASDAQ
add
Delcath Systems, Inc.
9,14 $
Après la clôture :(0,00 %)0,00
9,14 $
Fermé : 27 sept., 16:30:00 UTC−4 · USD · NASDAQ · Clause de non-responsabilité
Dernière clôture
8,87 $
Variation sur la journée
8,88 $ - 9,23 $
Plage sur l'année
2,25 $ - 11,75 $
Capitalisation boursière
255,78 M USD
Volume moyen
309,11 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 7,77 M | 1 468,89 % |
Charges d'exploitation | 10,16 M | 21,78 % |
Résultat net | -13,74 M | -90,79 % |
Marge bénéficiaire nette | -176,94 | 87,84 % |
Bénéfice par action | -0,48 | 17,24 % |
EBITDA | -3,88 M | 51,32 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 19,91 M | 36,91 % |
Total des actifs | 33,91 M | 61,11 % |
Total du passif | 13,91 M | -20,56 % |
Total des capitaux propres | 20,00 M | — |
Actions en circulation | 28,00 M | — |
Ratio cours/valeur comptable | 59,13 | — |
Rentabilité des actifs | -27,94 % | — |
Retour sur capitaux | -35,67 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -13,74 M | -90,79 % |
Trésorerie (opérations) | -4,45 M | 53,87 % |
Trésorerie (invest.) | 10,28 M | 25 810,00 % |
Trésorerie (financement) | -2,85 M | -40 871,43 % |
Variation nette en trésorerie | 2,97 M | 130,70 % |
Flux de trésorerie dispo. | -2,46 M | 62,43 % |
À propos
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Date de fondation
1988
Siège social
Site Web
Employés
76
